{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '3.', 'STUDY DESIGN OVERVIEW', 'Protocol waivers or exemptions are not allowed unless necessary for the management of', 'immediate safety concerns. Therefore, adherence to the study design requirements,', 'including those specified in the outline of study procedures (Section 6), are essential and', 'required for study conduct.', 'Figure 2 presents an overview of the study design.', 'Figure 2', 'Study design overview', 'Moderate to very severe', 'COPD patients', '3 40 years', 'Scheduled', 'Screening Visit', 'V1', 'V2', 'V3', '(stable) visits', '(Pre-month 0)', 'MO', 'M6', 'M12', '(V1,V2,V3)', '-', 'Spiro, Chest X-Ray,', 'e-DC, SP', 'SP', 'Spiro SP', 'for all subjects', 'e-DC, SP, ATS-DLD-078,', 'CAT,SGRQ-C', 'CAT, SGRQ-C', 'CAT, SGRQ-C,', 'Biomass exposure', 'BS', 'BS', 'AECOPD visit during', 'AECOPD and follow-up', 'AECOPD', 'Follow -up', 'phone call(s)', 'visit', 'phone call(s)', '-', 'SP *,CAT', 'for each AECOPD', 'Epoch 001', 'V = Visit; M = Month; SP = sputum sample; e-DC: Training and use of electronic Diary card; CAT = COPD', \"assessment test; SGRQ- = St. George's Respiratory Questionnaire for COPD patients; spiro = spirometry ;\", 'BS = Blood Sampling; AECOPD = acute exacerbation of COPD; ATS-DLD-078 = American Thoracic Society', 'and National Heart and Lung Institute-Division of Lung Disease Respiratory Questionnaire', '* The sputum samples during AECOPD should preferably be obtained before administration of the first dose of', 'antibiotics to treat the AECOPD (if applicable). Self collection of the sputum sample will be allowed in specific', 'cases, where the first dose of antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'This is not allowed at scheduled visits when subject should be in stable condition.', 'Follow- up phone calls will take place at least every 2 weeks, until the AECOPD has resolved', 'Type of design: Prospective, epidemiological, interventional, multi-country, cohort study.', 'Study population: A cohort of approximately 200 moderate to very severe COPD', 'patients with at least 1 documented moderate or severe AECOPD in the year before', 'enrolment.', 'Type of study: self-contained.', 'Data collection: Electronic Case Report Form (eCRF) and electronic diary cards.', 'Primary completion Date: Visit 3 (Month 12). Refer to glossary of terms for the', 'definition of PCD.', 'End of Study (EoS): Last testing results released of samples collected at Visit 3.', 'Duration of the study: The study will last approximately 1 year for each subject from', 'screening visit up to study conclusion.', '19-OCT-2018', '32', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Note: Screening visit should ideally occur not more than 6 weeks before visit 1.', '-', 'Epoch 001: Prospective data collection starting at Screening Visit (Pre-month 0)', 'and ending at Visit 3 (Month 12).', 'Table 3', 'Study groups and epochs foreseen in the study', 'Number of', 'Epoch', 'Study Groups', 'Age', 'subjects', 'Epoch 001', 'Prospective', 'Approx 200', '40 years', 'X', 'Study visits/contacts:', '- Screening visit.', '- Three scheduled (stable) study visits occurring at 6 months intervals.', '-', 'For each AECOPD: AECOPD visit (within 96 hours of the onset of the', 'symptoms) and follow-up phone call(s) (at least every 2 weeks until the', 'AECOPD has resolved). Follow-up phone contacts will define end of AECOPD.', 'COPD symptoms', 'Subjects will be asked to record their COPD symptoms in an electronic Diary Card', 'on a daily basis:', '-', 'Daily in the morning throughout the study: Morning symptoms questionnaire.', '- Daily at bedtime throughout the study: EXACT-PRO (EXAcerbations of Chronic', 'Pulmonary Disease Tool - Patient Reported Outcome) questionnaire.', 'Biological samples:', '-', 'Sputum samples collected at site (spontaneous or induced, as per investigator', 'judgement) will be collected at each study visit at the site (scheduled [stable]', 'visits and AECOPD visits) if, in the opinion of the investigator, it is safe for the', 'subject.', 'Or', \"- Sputum sample collected at subject's home (spontaneous). Self-collection of\", 'the sputum sample will be allowed in specific cases, where the first dose of', 'antibiotics absolutely needs to be taken before an AECOPD visit can take place.', 'This is not allowed at scheduled visits when subject should be in stable condition.', 'Note: The sputum samples collected during AECOPD should preferably be obtained', 'before administration of the first dose of antibiotics to treat the AECOPD (if applicable).', '-', 'Blood samples for biomarker testing will be collected at Visit 1 (M0) and Visit', '3 (M12).', '19-OCT-2018', '33', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}